Company intelligence / Profile preview
Telomere Therapeutics
Barcelona, Catalonia, Spaintelomere-tx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical results demonstrate, for the first time, disease reversal in animal models of idiopathic pulmonary fibrosis via TERT/AAV gene therapy. The company aims to translate these findings into clinical reality for IPF patients. No clinical trial data available yet; IND-enabling studies ongoing or planned.
- Therapeutic areas
- Rare DiseasesPulmonologyOther
- Modalities
- Gene therapyAdeno-associated viral vector-based therapy (AAV-based gene therapy)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Initial investment from Invivo Ventures/Invivo Capital, whose partners joined the board of directors.Academic founding partners include CNIO and UAB.
Beyond the preview
Go deeper on Telomere Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telomere Therapeutics.